Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: Antibodies, Monoclonal; Nivolumab; Pembrolizumab

Criteria

Inclusion Criteria:

• Diagnosis of urothelial carcinoma

• Adequate bone marrow and organ function

Exclusion Criteria:

• Uncontrolled tumor in the brain

• Unacceptable toxicity with prior checkpoint inhibitor

• Impaired heart function